Obsace-ER 100mg Tablet contains Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of obsessive-compulsive disorder (OCD) and major depressive disorder (MDD). Fluvoxamine acts by inhibiting the reuptake of serotonin in the central nervous system, thereby increasing serotonin levels and enhancing neurotransmission. This extended-release formulation allows for once-daily dosing, improving patient compliance and maintaining stable plasma concentrations. Obsace-ER is prescribed to alleviate symptoms such as persistent intrusive thoughts, compulsive behaviors, and depressive episodes, contributing to improved daily functioning and quality of life. The medication should be initiated under medical supervision, with dosage adjustments based on clinical response and tolerability. Common adverse effects may include nausea, headache, insomnia, and gastrointestinal disturbances, which are generally transient. Caution is advised in patients with hepatic impairment, as metabolism may be affected. Fluvoxamine may interact with other serotonergic agents, increasing the risk of serotonin syndrome, and with drugs metabolized by cytochrome P450 enzymes. It is contraindicated in individuals with hypersensitivity to the drug or concurrent use of monoamine oxidase inhibitors (MAOIs). Regular monitoring for therapeutic efficacy and adverse reactions is recommended throughout the treatment course.